---
title: "Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293659753.md"
description: "Genmab clarified primary endpoints for the Phase 3 EPCORE DLBCL-1 trial of epcoritamab. In the U.S., overall survival was the sole primary endpoint, which the study missed with no statistically significant improvement. The trial uses region-specific endpoints, differing from earlier messaging, with additional results pending journal submission."
datetime: "2026-07-23T20:00:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293659753.md)
  - [en](https://longbridge.com/en/news/293659753.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293659753.md)
generator: "portal-rs"
---

# Genmab, AbbVie clarify primary endpoints in Phase 3 EPCORE DLBCL-1 trial

-   Genmab issued a clarification correcting how primary endpoints were described for the Phase 3 EPCORE DLBCL-1 epcoritamab trial. \* In the U.S., overall survival was the sole primary endpoint; the study missed it, with no statistically significant overall survival improvement. \* The trial uses region-specific primary endpoints, creating a mismatch with earlier topline messaging; additional results are slated for journal submission. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723712759) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [Genmab executive team joins fireside chats at upcoming investor healthcare conferences](https://longbridge.com/en/news/296918621.md)
- [Weekly Recap: Epcoritamab‑lenalidomide PFS success and 2026 royalties rise](https://longbridge.com/en/news/295360680.md)
- [China approves J&J's oral psoriasis pill, says drugmaker](https://longbridge.com/en/news/297158718.md)
- [Genmab H1 FY26 operating profit rises 1% to USD 555 million; revenue increases 25% to USD 2.05 billion](https://longbridge.com/en/news/295122919.md)
- [How Investors Are Reacting To Genmab (CPSE:GMAB) Epcoritamab’s Phase 3 Overall-Survival Miss in DLBCL](https://longbridge.com/en/news/294654892.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**